(Q24241045)

inferred from title

author

Dirk J van Veldhuisen

6

object named as

Dirk J van Veldhuisen

0 references

author name string

Katherine Ngo

1

0 references

Dipak Kotecha

2

0 references

Julia AE Walters

3

0 references

Luis Manzano

4

0 references

Alberto Palazzuoli

5

0 references

Marcus Flather

Cochrane Database of Systematic Reviews

7

0 references

publication date

20 January 2010

0 references

published in

0 references

cites work

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia and its relationship to clinical outcome in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Heart failure and anemia: mechanisms and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Erythropoietin or Darbepoetin for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The heart failure epidemic: exactly how big is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Fatigue and anaemia in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia as a risk factor and therapeutic target in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Erythropoietin: physiology and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia and mortality in heart failure patients a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Erythropoiesis-stimulating agent hyporesponsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

New avenues of exploration for erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Pathophysiology of anaemia: focus on the heart and blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Emerging role of anemia in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Erythropoietin treatment in patients with chronic heart failure: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Monitoring clinical changes in patients with heart failure: A comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Analysing Data and Undertaking Meta-Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Selecting Studies and Collecting Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

Anemia in chronic heart failure: pathogenetic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Intravenous iron alone for the treatment of anemia in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Working capacity is increased following recombinant human erythropoietin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Prothrombotic effect of erythropoietin in dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Hemodynamic characteristics during treadmill and bicycle exercise in chronic heart failure: mechanism for different responses of peak oxygen uptake

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021

Comparison of treadmill and bicycle exercise in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007613.PUB2

7 January 2021